A Disease Managed in the Dark Ages

The clinical picture is stark. Endometriosis lesions are frequently too small—often under 2mm—to be detected by MRI, CT, or conventional ultrasound. Patients cycle through hormonal treatments prescribed without imaging guidance, return in six months, and repeat. When treatment fails, actual diagnosis still often requires surgery.

"Patients are being ignored and dismissed with 'it's in your head,'" Ziso explains. "They are prescribed psychiatric drugs. And in order to prove they are not crazy, they are forced to undergo laparoscopic surgery for the sole purpose of diagnosis."

The problem is not physician indifference, it's a tool gap. Professor Marc R. Laufer, MD, chief of gynecology at Boston Children's Hospital and a professor at Harvard Medical School, states it plainly: "Numerous conditions, including superficial peritoneal endometriosis, remain invisible to current imaging technologies. EndoCure's development of an imaging modality capable of detecting endometriosis or cancers at an early stage would be transformative, revolutionizing diagnosis and expanding treatment options."

The Fundraising Backdoor

Ziso holds a PhD in medical robotics from the Technion–Israel Institute of Technology and spent 20 years building medical devices, including leading a prostate cancer application from preclinical trials through FDA approval. She knows how to build. Fundraising for women's health, she found, is a separate skill set entirely.

Diagnostic companies already face a harder road than therapeutics. Add women's health, and the challenge compounds. "There are a lot of talks about women's health," Ziso acknowledges. "I heard that JP Morgan published that there's a lot of interest, a lot of money, but it still didn't get to us founders."

Recent data tracking exits in women's health show the sector surpassing $100 billion in exits, a number that generated real momentum. But Ziso's experience suggests the energy at conferences and the term sheets reaching founders remain two different things. Women's health exits surpassed records while structural funding gaps persist.

Her solution: Find the backdoor. Repositioning around oncology and general imaging—capabilities Revealan genuinely has—opened doors that endometriosis alone could not. The pivot reflects real technical capability, not misdirection. But the fact that a founder building technology for 190 million women had to lead with cancer to get a meeting is an anomaly that the capital market has not yet explained.

Teuza Fund made the bet. Gil Kerbs explains what convinced him: "I love two things about EndoCure. First is that they have 10X resolution, allowing clinicians to see things they could never see before, such as very early-stage cancer, which is a clinical breakthrough. Second, I see this company as creating a new way of acquiring high-quality healthcare data. It opens the door to AI to really start making a big impact in this space, which was not possible in the past since ultrasound produces very low-quality images that AI had very little to work with."

Press the Button, Get the Same Result

Revealan attaches to any existing off-the-shelf ultrasound transducer. It moves the probe with mechanical precision across the abdominal and pelvic area, producing a standardized, high-density, 3D image at least 10 times the density of an MRI—at roughly one-tenth the cost per scan.

"Any technician anywhere can press the button and get exactly the same results to be sent for interpretation by the radiologist," Ziso notes. "That simply doesn't exist today in ultrasound imaging."

David P. Cernicek, RVT (Registered Vascular Technologist) and RDMS (Registered Diagnostic Medical Sonographer), an ultrasound industry consultant with 45 years of experience, puts it in context. "With 45 years in ultrasound and decades working in 3D and robotic guidance, I've watched the technology move from operator-dependent imaging toward reproducible precision, “ he said. “EndoCure accelerates that shift by uniting robotics, volumetric 3D with Multiplane-Reconstruction, and AI into a single, clinically practical platform."

The economics are built for adoption. EndoCure's model starts with a $10,000 down payment and a subscription calculated at $120 per scan, reimbursable under existing CPT codes. Compare that to $1 million-plus in MRI infrastructure and approximately $1,000 out-of-pocket per scan.

The Catch-22 Blocking a Cure

There is no cure for endometriosis. Understanding why requires understanding the clinical trial problem behind it.

To run a drug trial, pharmaceutical companies must assess lesion response before and after drug administration. The only objective method with current tools is laparoscopic surgery—twice. That enrollment barrier has quietly stalled a viable drug development pipeline. No non-invasive monitoring tool means no scalable trial. No scalable trial means no approved drug.

"We can totally change this process," Ziso contends, "allowing a non-invasive way for monitoring drug effects and, potentially, unlocking the door for new emerging drugs into this field."

This is the dimension of EndoCure's potential that most coverage has missed. Revealan is not only a diagnostic platform—it may be the infrastructure that makes endometriosis drug trials feasible at scale, and determines whether a cure is ever developed.

The Table Is Not Yet Set

The backdoor worked. EndoCure has raised $2.7 million and is advancing clinical studies including a bladder cancer monitoring trial, with FDA 510(k) clearance in its sights. The technology is real. The clinical interest is documented.

But a backdoor is not a solution. Ziso is clear about what still needs to change:

"We need to bring the men into the story. We had one man at the table and about 20 women. We have to bring [men] to the table, into the story, before we even succeed in fundraising for women's health."

The structural irony holds on both sides. The same invisibility that makes endometriosis so hard to diagnose—lesions too small to see, symptoms too easy to dismiss—makes it hard to fund. EndoCure's argument, made in steel and software rather than advocacy, is that if you can make the lesions visible, the rest eventually follows.